Significantly longer overall and progression-free survival seen among patients with limited-stage small cell lung cancer
Improved progression-free survival seen for amivantamab-lazertinib versus osimertinib as first-line treatment
Significantly longer progression-free survival, but not overall survival, seen for osimertinib in unresectable EGFR-mutation NSCLC
Findings seen among patients with resected ALK-positive non-small cell lung cancer
Significant benefit seen for neoadjuvant tislelizumab plus chemotherapy with adjuvant tislelizumab
Improved median overall survival and progression-free survival seen for pegargiminase-based chemotherapy
Greater incidence of grade 3 or higher adverse events from any cause seen in combination group versus monotherapy
Improvement in overall survival seen for patients receiving cisplatin or carboplatin with pemetrexed
More patients taking alectinib with low-fat yogurt do not reach the exposure threshold of 435 ng/mL
In phase 2 trial, overall survival longer with combo treatment compared with investigator's choice for standard of care in advanced NSCLC